US equities
|
NVDA
$239.67
▲+2.44%
SPCX
$169.60
▲+6.69%
MU
$1,061.38
▼-1.26%
TSLA
$380.97
▲+2.80%
SNDK
$1,694.64
▼-1.47%
MSFT
$528.17
▲+2.06%
INTC
$116.40
▼-2.46%
META
$742.66
▲+2.00%
NVDA
$239.67
▲+2.44%
SPCX
$169.60
▲+6.69%
MU
$1,061.38
▼-1.26%
TSLA
$380.97
▲+2.80%
SNDK
$1,694.64
▼-1.47%
MSFT
$528.17
▲+2.06%
INTC
$116.40
▼-2.46%
META
$742.66
▲+2.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Immunoprecise Antibodies Ltd
(TSV:
IPA
)
N/A
UNCHANGED
Last Price
Updated: 3:58 PM EST, Nov 25, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunoprecise Antibodies Ltd
ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange
November 22, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA’s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs
October 12, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75
September 14, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023
September 14, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022
September 08, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Live Virus Assays at Ludwig-Maximilians-Universität München Confirm PolyTope’s Efficacy Against SARS-CoV-2 Variants Including BA.5
August 29, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022
July 29, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022
July 26, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2
July 12, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern
April 20, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant
May 09, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings
April 14, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre
October 07, 2021
From
ImmunoPrecise Antibodies Ltd
Via
Business Wire
